Additionally, studies have demonstrated the clinical relevance of Tks5 expression in cancer, such as glial-derived brain tumors, lung adenocarcinomas, prostate cancer and breast cancer [21, 38–40]. Here, SH3PXD2A is linked to prostate cancer.